MAS
RVMD icon

Meeder Advisory Services’s Revolution Medicines RVMD Stock Holding History

Meeder Advisory Services’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$735K Sell
3,922
-204
-5% -$29.8K 0.03% 348
2026
Q1 		$401K Buy
4,126
+120
+3% +$12.1K 0.02% 448
2025
Q4 		$319K Buy
+4,006
New +$263K 0.01% 503

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Meeder Advisory Services's RVMD Position: Q2 2026 in Review

Meeder Advisory Services reduced its Revolution Medicines (RVMD) stake by 4.9% in Q2 2026, selling an estimated $29.8K and leaving 3,922 shares worth $735K. The position accounts for 0.03% of the portfolio, ranked #348.

Meeder Advisory Services first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Meeder Advisory Services held 3,922 shares of Revolution Medicines worth $735K as of Q2 2026.
  • Meeder Advisory Services sold 204 Revolution Medicines shares in Q2 2026, an estimated $29.8K.
  • Revolution Medicines made up 0.03% of Meeder Advisory Services's portfolio in Q2 2026, its #348 holding.
  • Meeder Advisory Services first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.